Core Viewpoint - HCM (HCM.US) shares rose over 5% to $16.12 following the publication of SACHI III trial results in The Lancet, highlighting the potential of savolitinib and osimertinib combination therapy for specific lung cancer patients [1] Group 1: Company Overview - HCM announced the results of the SACHI III trial, which focuses on the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who progressed after first-line EGFR TKI treatment [1] - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and HCM, with AstraZeneca responsible for commercialization [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] Group 2: Research and Approval - The SACHI study data supports the approval of the savolitinib and osimertinib combination therapy, which is expected to be granted in China by June 2025 [1]
和黄医药(HCM.US)涨逾5% SACHI III期研究结果于《柳叶刀》发表